Sulfasalazine in Patients With Metastatic Colorectal Cancer - Trial NCT06134388
Access comprehensive clinical trial information for NCT06134388 through Pure Global AI's free database. This Phase 3 trial is sponsored by Tanta University and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tanta University
Timeline & Enrollment
Phase 3
Sep 01, 2023
Sep 01, 2026
Primary Outcome
Evaluating the change in the serum level of Ferritin,Evaluating the change in the serum level of Superoxide dismutase (SOD),Evaluating the change in the serum level of Nuclear factor-kappa B (NF-kB),Evaluating the change in the serum level of Bcl-2 associated X protein (Bax),Investigating the possible efficacy of sulfasalazine through evaluation of its impact on overall response rate (ORR).,Investigating the possible efficacy of sulfasalazine through evaluation of its impact on disease control rate (DCR).
Summary
The aim of this study is to evaluate the potential efficacy and safety of sulfasalazine in
 patients with metastatic colorectal cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06134388
Non-Device Trial